| PRECLINICAL | evidence | Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Obesity in China: current progress and future prospects. | Tirzepatide | Weight & fat loss | 2026-02-01 |
| PRECLINICAL | evidence | Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years. | Tirzepatide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | Delayed-Onset Amiodarone Induced Thyrotoxicosis After Glucagon-Like Peptide-1 Agonist-Related Weight Loss. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review. | Tirzepatide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis. | Tirzepatide | Weight & fat loss | 2026-02-01 |
| PRECLINICAL | evidence | Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. | Tirzepatide | Inflammation | 2026-02-01 |
| PRECLINICAL | evidence | FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Correction to: "Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures". | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Management of Obesity in Psoriasis Consultations. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | A Fluorescent Probe-Based Platform for Precise Pharmaceutical Analysis and Quality Assessment of Tirzepatide. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. | Tirzepatide | Weight & fat loss | 2026-02-01 |
| PRECLINICAL | evidence | Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide. | Tirzepatide | Weight & fat loss | 2026-02-01 |
| PRECLINICAL | evidence | Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients. | Tirzepatide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. | Tirzepatide | — | 2026-01-28 |
| PRECLINICAL | evidence | A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal. | Tirzepatide | — | 2026-01-27 |
| PRECLINICAL | evidence | Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. | Tirzepatide | — | 2026-01-26 |
| PRECLINICAL | evidence | Resolution of severe lumbar spinal epidural lipomatosis following tirzepatide-induced weight loss: illustrative case. | Tirzepatide | — | 2026-01-26 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions. | Tirzepatide | — | 2026-01-23 |
| PRECLINICAL | evidence | Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity. | Tirzepatide | Weight & fat loss | 2026-01-21 |
| PRECLINICAL | evidence | Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia. | Tirzepatide | — | 2026-01-19 |
| PRECLINICAL | evidence | Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service. | Tirzepatide | Weight & fat loss | 2026-01-15 |
| PRECLINICAL | evidence | Pharmacological Management of Diabesity: Current and Emerging Therapies. | Tirzepatide | Glycemic control | 2026-01-13 |
| PRECLINICAL | evidence | Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems. | Tirzepatide | — | 2026-01-13 |
| PRECLINICAL | evidence | Mounjaro: Experts issue warning over black market jabs, with fifth of areas still lacking NHS access. | Mounjaro | — | 2026-01-09 |
| PRECLINICAL | evidence | Assessment of community awareness and attitude about the use of GLP 1 agonists as a treatment for obesity in Saudi Arabia: Cross-sectional study. | Mounjaro | — | 2026-01-09 |
| PRECLINICAL | evidence | Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. | Mounjaro | — | 2026-01-08 |
| PRECLINICAL | evidence | Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. | Tirzepatide | — | 2026-01-06 |
| PRECLINICAL | evidence | Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials. | Tirzepatide | Glycemic control | 2026-01-05 |
| PRECLINICAL | evidence | Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends. | Tirzepatide | — | 2026-01-05 |
| PRECLINICAL | evidence | Beyond metabolism: sexual dysfunction and weight-loss drugs. | Tirzepatide | Weight & fat loss | 2026-01-02 |
| PRECLINICAL | evidence | Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists. | Tirzepatide | — | 2026-01-02 |
| PRECLINICAL | evidence | Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Incretin therapy and obesity: current and future pharmacologic possibilities. | Zepbound | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Correction: Weight loss efficiency and safety of tirzepatide: A Systematic review. | Tirzepatide | — | 2026-01-01 |